{"name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","slug":"johnson-johnson-pharmaceutical-research-development-l-l-c","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":16,"colorKey":"cardiovascular","drugs":[{"name":"Paliperidone ER","genericName":"Paliperidone ER","slug":"paliperidone-er","indication":"Other","status":"marketed"},{"name":"Pentosan polysulfate sodium 100 mg","genericName":"Pentosan polysulfate sodium 100 mg","slug":"pentosan-polysulfate-sodium-100-mg","indication":"Other","status":"marketed"},{"name":"doripenum","genericName":"doripenum","slug":"doripenum","indication":"Other","status":"phase_3"},{"name":"14C-JNJ-39823277","genericName":"14C-JNJ-39823277","slug":"14c-jnj-39823277","indication":"Other","status":"phase_1"},{"name":"14C-JNJ26489112","genericName":"14C-JNJ26489112","slug":"14c-jnj26489112","indication":"Other","status":"phase_1"},{"name":"Becaplermin users","genericName":"Becaplermin users","slug":"becaplermin-users","indication":"Ulcerative wounds","status":"phase_2"},{"name":"Current Domperidone","genericName":"Current Domperidone","slug":"current-domperidone","indication":"Gastroparesis","status":"phase_2"},{"name":"JNJ 40929837","genericName":"JNJ 40929837","slug":"jnj-40929837","indication":"Other","status":"phase_2"},{"name":"Other atypical antipsychotic drugs","genericName":"Other atypical antipsychotic drugs","slug":"other-atypical-antipsychotic-drugs","indication":"Other","status":"marketed"},{"name":"Pancrease MT 10.5, or MT 21","genericName":"Pancrease MT 10.5, or MT 21","slug":"pancrease-mt-10-5-or-mt-21","indication":"Exocrine pancreatic insufficiency","status":"phase_3"},{"name":"Placebo for Pancrease MT 10.5 or MT 21","genericName":"Placebo for Pancrease MT 10.5 or MT 21","slug":"placebo-for-pancrease-mt-10-5-or-mt-21","indication":"Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions","status":"phase_3"},{"name":"ULTRAM ER","genericName":"ULTRAM ER","slug":"ultram-er","indication":"Other","status":"marketed"},{"name":"norelgestromin + ethinyl estradiol","genericName":"norelgestromin + ethinyl estradiol","slug":"norelgestromin-ethinyl-estradiol","indication":"Contraception (prevention of pregnancy)","status":"marketed"},{"name":"norelgestromin + ethinyl estradiol; mercilon","genericName":"norelgestromin + ethinyl estradiol; mercilon","slug":"norelgestromin-ethinyl-estradiol-mercilon","indication":"Contraception","status":"phase_3"},{"name":"norelgestromin + ethinyl estradiol; triphasil.","genericName":"norelgestromin + ethinyl estradiol; triphasil.","slug":"norelgestromin-ethinyl-estradiol-triphasil","indication":"Contraception","status":"phase_3"},{"name":"risperidone, quetiapine","genericName":"risperidone, quetiapine","slug":"risperidone-quetiapine","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"immunology","drugs":[{"name":"Extended-release galantamine hydrobromide","genericName":"Extended-release galantamine hydrobromide","slug":"extended-release-galantamine-hydrobromide","indication":"Mild to moderate Alzheimer's disease","status":"phase_3"},{"name":"Risperidone low dose","genericName":"Risperidone low dose","slug":"risperidone-low-dose","indication":"Schizophrenia","status":"marketed"},{"name":"Risperidone, oral tablets","genericName":"Risperidone, oral tablets","slug":"risperidone-oral-tablets","indication":"Schizophrenia","status":"phase_3"},{"name":"14C-paliperidone","genericName":"14C-paliperidone","slug":"14c-paliperidone","indication":"Schizophrenia","status":"phase_1"},{"name":"Abilify","genericName":"Abilify","slug":"abilify","indication":"Agitation associated with Bipolar Mania","status":"marketed"},{"name":"ER OROS Paliperidone","genericName":"ER OROS Paliperidone","slug":"er-oros-paliperidone","indication":"Schizophrenia","status":"phase_3"},{"name":"Paliperidone ER OROS","genericName":"Paliperidone ER OROS","slug":"paliperidone-er-oros","indication":"Schizophrenia","status":"phase_3"},{"name":"Risperidone high dose","genericName":"Risperidone high dose","slug":"risperidone-high-dose","indication":"Schizophrenia","status":"marketed"},{"name":"Topiramate; Carbamazepine; Valproate","genericName":"Topiramate; Carbamazepine; Valproate","slug":"topiramate-carbamazepine-valproate","indication":"Partial onset seizures","status":"phase_3"},{"name":"topiramate, phenytoin","genericName":"topiramate, phenytoin","slug":"topiramate-phenytoin","indication":"Seizure prevention in patients with epilepsy","status":"phase_3"},{"name":"topiramate, propranolol","genericName":"topiramate, propranolol","slug":"topiramate-propranolol","indication":"Seizure prevention in patients with epilepsy","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Tipifarnib;Zarnestra; R115777","genericName":"Tipifarnib;Zarnestra; R115777","slug":"tipifarnib-zarnestra-r115777","indication":"Acute myeloid leukemia","status":"phase_3"},{"name":"Epoetin alfa once every two weeks","genericName":"Epoetin alfa once every two weeks","slug":"epoetin-alfa-once-every-two-weeks","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Gemcitabine with R115777","genericName":"Gemcitabine with R115777","slug":"gemcitabine-with-r115777","indication":"Pancreatic cancer","status":"phase_3"},{"name":"Epoetin alfa 3 times weekly /once weekly","genericName":"Epoetin alfa 3 times weekly /once weekly","slug":"epoetin-alfa-3-times-weekly-once-weekly","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Epoetin alfa once weekly","genericName":"Epoetin alfa once weekly","slug":"epoetin-alfa-once-weekly","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Yondelis","genericName":"Yondelis","slug":"yondelis","indication":"Leiomyosarcoma","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Tapentadol ER (CG5503)","genericName":"Tapentadol ER (CG5503)","slug":"tapentadol-er-cg5503","indication":"Chronic pain","status":"phase_3"},{"name":"CG 5503;tapentadol","genericName":"CG 5503;tapentadol","slug":"cg-5503-tapentadol","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"CG5503 IR; tapentadol","genericName":"CG5503 IR; tapentadol","slug":"cg5503-ir-tapentadol","indication":"Acute pain management","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"CG5503","genericName":"CG5503","slug":"cg5503","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Canagliflozin (JNJ-28431754)","genericName":"Canagliflozin (JNJ-28431754)","slug":"canagliflozin-jnj-28431754","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"JNJ16269110","genericName":"JNJ16269110","slug":"jnj16269110","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"respiratory","drugs":[{"name":"levofloxacin, azithromycin, amoxicillin/clavulanate","genericName":"levofloxacin, azithromycin, amoxicillin/clavulanate","slug":"levofloxacin-azithromycin-amoxicillin-clavulanate","indication":"Community-acquired pneumonia","status":"phase_3"},{"name":"levofloxacin; amoxicillin/clavulanate","genericName":"levofloxacin; amoxicillin/clavulanate","slug":"levofloxacin-amoxicillin-clavulanate","indication":"Community-acquired pneumonia","status":"phase_3"},{"name":"levofloxacin; metronidazole","genericName":"levofloxacin; metronidazole","slug":"levofloxacin-metronidazole","indication":"Mixed aerobic and anaerobic bacterial infections","status":"marketed"}]}],"pipeline":[{"name":"Tipifarnib;Zarnestra; R115777","genericName":"Tipifarnib;Zarnestra; R115777","slug":"tipifarnib-zarnestra-r115777","phase":"phase_3","mechanism":"Tipifarnib is a farnesyltransferase inhibitor that blocks the farnesylation of Ras proteins, which are involved in cell signaling and proliferation.","indications":["Acute myeloid leukemia","Basal cell carcinoma"],"catalyst":""},{"name":"Epoetin alfa once every two weeks","genericName":"Epoetin alfa once every two weeks","slug":"epoetin-alfa-once-every-two-weeks","phase":"phase_3","mechanism":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing elective surgery"],"catalyst":""},{"name":"Extended-release galantamine hydrobromide","genericName":"Extended-release galantamine hydrobromide","slug":"extended-release-galantamine-hydrobromide","phase":"phase_3","mechanism":"Galantamine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking its breakdown, and also acts as an allosteric modulator of nicotinic receptors.","indications":["Mild to moderate Alzheimer's disease"],"catalyst":""},{"name":"Gemcitabine with R115777","genericName":"Gemcitabine with R115777","slug":"gemcitabine-with-r115777","phase":"phase_3","mechanism":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while R115777 is a farnesyltransferase inhibitor that blocks Ras protein activation, together targeting cancer cell proliferation through complementary pathways.","indications":["Pancreatic cancer","Advanced solid tumors"],"catalyst":""},{"name":"Paliperidone ER","genericName":"Paliperidone ER","slug":"paliperidone-er","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pentosan polysulfate sodium 100 mg","genericName":"Pentosan polysulfate sodium 100 mg","slug":"pentosan-polysulfate-sodium-100-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Risperidone low dose","genericName":"Risperidone low dose","slug":"risperidone-low-dose","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Irritability associated with autism spectrum disorder","Aggression and behavioral disturbances in dementia"],"catalyst":""},{"name":"Risperidone, oral tablets","genericName":"Risperidone, oral tablets","slug":"risperidone-oral-tablets","phase":"phase_3","mechanism":"Risperidone is an atypical antipsychotic that acts as a dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist.","indications":["Schizophrenia","Bipolar disorder"],"catalyst":""},{"name":"Tapentadol ER (CG5503)","genericName":"Tapentadol ER (CG5503)","slug":"tapentadol-er-cg5503","phase":"phase_3","mechanism":"Tapentadol ER is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor.","indications":["Chronic pain","Acute pain"],"catalyst":""},{"name":"doripenum","genericName":"doripenum","slug":"doripenum","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-JNJ-39823277","genericName":"14C-JNJ-39823277","slug":"14c-jnj-39823277","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-JNJ26489112","genericName":"14C-JNJ26489112","slug":"14c-jnj26489112","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-paliperidone","genericName":"14C-paliperidone","slug":"14c-paliperidone","phase":"phase_1","mechanism":"Dopamine D2 receptor antagonist","indications":["Schizophrenia"],"catalyst":""},{"name":"Abilify","genericName":"Abilify","slug":"abilify","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","indications":["Agitation associated with Bipolar Mania","Agitation associated with Schizophrenia","Bipolar affective disorder, current episode manic","Bipolar disorder in remission","Depression Treatment Adjunct"],"catalyst":""},{"name":"Becaplermin users","genericName":"Becaplermin users","slug":"becaplermin-users","phase":"phase_2","mechanism":"Stimulates wound healing by promoting the proliferation and differentiation of keratinocytes and fibroblasts","indications":["Ulcerative wounds"],"catalyst":""},{"name":"CG 5503;tapentadol","genericName":"CG 5503;tapentadol","slug":"cg-5503-tapentadol","phase":"phase_3","mechanism":"Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor that provides analgesia through dual mechanisms.","indications":["Moderate to severe acute pain","Moderate to severe chronic pain"],"catalyst":""},{"name":"CG5503","genericName":"CG5503","slug":"cg5503","phase":"phase_3","mechanism":"CG5503 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CG5503 IR; tapentadol","genericName":"CG5503 IR; tapentadol","slug":"cg5503-ir-tapentadol","phase":"phase_3","mechanism":"Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor that provides analgesia through dual mechanisms of action.","indications":["Acute pain management","Moderate to severe pain"],"catalyst":""},{"name":"Canagliflozin (JNJ-28431754)","genericName":"Canagliflozin (JNJ-28431754)","slug":"canagliflozin-jnj-28431754","phase":"phase_3","mechanism":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing reabsorption of glucose and promoting urinary glucose excretion to lower blood glucose levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Current Domperidone","genericName":"Current Domperidone","slug":"current-domperidone","phase":"phase_2","mechanism":"Current Domperidone acts as a dopamine D2 receptor antagonist.","indications":["Gastroparesis"],"catalyst":""},{"name":"ER OROS Paliperidone","genericName":"ER OROS Paliperidone","slug":"er-oros-paliperidone","phase":"phase_3","mechanism":"Paliperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","indications":["Schizophrenia","Schizoaffective disorder","Bipolar I disorder (acute mania)"],"catalyst":""},{"name":"Epoetin alfa 3 times weekly /once weekly","genericName":"Epoetin alfa 3 times weekly /once weekly","slug":"epoetin-alfa-3-times-weekly-once-weekly","phase":"phase_3","mechanism":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in cancer patients receiving chemotherapy","Anemia in patients with HIV infection on antiretroviral therapy"],"catalyst":""},{"name":"Epoetin alfa once weekly","genericName":"Epoetin alfa once weekly","slug":"epoetin-alfa-once-weekly","phase":"phase_3","mechanism":"Epoetin alfa is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with cancer receiving chemotherapy","Anemia in patients undergoing elective surgery"],"catalyst":""},{"name":"JNJ 40929837","genericName":"JNJ 40929837","slug":"jnj-40929837","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ16269110","genericName":"JNJ16269110","slug":"jnj16269110","phase":"phase_2","mechanism":"JNJ16269110 is a selective and potent antagonist of the human glucagon receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Other atypical antipsychotic drugs","genericName":"Other atypical antipsychotic drugs","slug":"other-atypical-antipsychotic-drugs","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paliperidone ER OROS","genericName":"Paliperidone ER OROS","slug":"paliperidone-er-oros","phase":"phase_3","mechanism":"Paliperidone ER OROS is an atypical antipsychotic that works by blocking dopamine receptors in the brain.","indications":["Schizophrenia","Schizoaffective disorder"],"catalyst":""},{"name":"Pancrease MT 10.5, or MT 21","genericName":"Pancrease MT 10.5, or MT 21","slug":"pancrease-mt-10-5-or-mt-21","phase":"phase_3","mechanism":"Pancrease MT is a pancreatic enzyme supplement used to treat exocrine pancreatic insufficiency.","indications":["Exocrine pancreatic insufficiency"],"catalyst":""},{"name":"Placebo for Pancrease MT 10.5 or MT 21","genericName":"Placebo for Pancrease MT 10.5 or MT 21","slug":"placebo-for-pancrease-mt-10-5-or-mt-21","phase":"phase_3","mechanism":"This is a placebo, meaning it has no active therapeutic effect.","indications":["Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions"],"catalyst":""},{"name":"Risperidone high dose","genericName":"Risperidone high dose","slug":"risperidone-high-dose","phase":"marketed","mechanism":"Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance)","Irritability associated with autism spectrum disorder","Treatment-resistant psychosis (at higher doses)"],"catalyst":""},{"name":"Topiramate; Carbamazepine; Valproate","genericName":"Topiramate; Carbamazepine; Valproate","slug":"topiramate-carbamazepine-valproate","phase":"phase_3","mechanism":"Topiramate is an anticonvulsant that acts as a voltage-dependent sodium channel blocker, whereas Carbamazepine is a tricyclic compound that stabilizes inactivated sodium channels, and Valproate is a fatty acid with anticonvulsant properties.","indications":["Partial onset seizures","Generalized seizures","Migraine prophylaxis"],"catalyst":""},{"name":"ULTRAM ER","genericName":"ULTRAM ER","slug":"ultram-er","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Yondelis","genericName":"Yondelis","slug":"yondelis","phase":"marketed","mechanism":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","indications":["Leiomyosarcoma","Liposarcoma","Malignant tumor of ovary","Soft or Connective Tissue Sarcoma"],"catalyst":""},{"name":"levofloxacin, azithromycin, amoxicillin/clavulanate","genericName":"levofloxacin, azithromycin, amoxicillin/clavulanate","slug":"levofloxacin-azithromycin-amoxicillin-clavulanate","phase":"phase_3","mechanism":"Levofloxacin, azithromycin, and amoxicillin/clavulanate inhibit bacterial growth through different mechanisms, targeting DNA gyrase, protein synthesis, and cell wall synthesis, respectively.","indications":["Community-acquired pneumonia","Acute bacterial sinusitis","Uncomplicated skin and skin structure infections"],"catalyst":""},{"name":"levofloxacin; amoxicillin/clavulanate","genericName":"levofloxacin; amoxicillin/clavulanate","slug":"levofloxacin-amoxicillin-clavulanate","phase":"phase_3","mechanism":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, while amoxicillin/clavulanate inhibits bacterial cell wall synthesis.","indications":["Community-acquired pneumonia","Skin and skin structure infections"],"catalyst":""},{"name":"levofloxacin; metronidazole","genericName":"levofloxacin; metronidazole","slug":"levofloxacin-metronidazole","phase":"marketed","mechanism":"This combination uses levofloxacin (a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV) and metronidazole (a nitroimidazole that damages bacterial DNA) to provide broad-spectrum anaerobic and aerobic bacterial coverage.","indications":["Mixed aerobic and anaerobic bacterial infections","Intra-abdominal infections","Pelvic inflammatory disease","Diabetic foot infections with mixed flora"],"catalyst":""},{"name":"norelgestromin + ethinyl estradiol","genericName":"norelgestromin + ethinyl estradiol","slug":"norelgestromin-ethinyl-estradiol","phase":"marketed","mechanism":"Norelgestromin and ethinyl estradiol work together as a hormonal contraceptive by suppressing ovulation through inhibition of gonadotropin-releasing hormone (GnRH) and feedback inhibition of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).","indications":["Contraception (prevention of pregnancy)","Regulation of menstrual cycle"],"catalyst":""},{"name":"norelgestromin + ethinyl estradiol; mercilon","genericName":"norelgestromin + ethinyl estradiol; mercilon","slug":"norelgestromin-ethinyl-estradiol-mercilon","phase":"phase_3","mechanism":"Norelgestromin and ethinyl estradiol are used to prevent pregnancy by suppressing ovulation and altering cervical mucus and the uterine lining.","indications":["Contraception"],"catalyst":""},{"name":"norelgestromin + ethinyl estradiol; triphasil.","genericName":"norelgestromin + ethinyl estradiol; triphasil.","slug":"norelgestromin-ethinyl-estradiol-triphasil","phase":"phase_3","mechanism":"Norelgestromin and ethinyl estradiol work together to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.","indications":["Contraception"],"catalyst":""},{"name":"risperidone, quetiapine","genericName":"risperidone, quetiapine","slug":"risperidone-quetiapine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"topiramate, phenytoin","genericName":"topiramate, phenytoin","slug":"topiramate-phenytoin","phase":"phase_3","mechanism":"Topiramate is an anticonvulsant that works by blocking voltage-dependent sodium channels, stabilizing neuronal membranes, and reducing the release of excitatory neurotransmitters.","indications":["Seizure prevention in patients with epilepsy","Migraine prevention"],"catalyst":""},{"name":"topiramate, propranolol","genericName":"topiramate, propranolol","slug":"topiramate-propranolol","phase":"phase_3","mechanism":"Topiramate is an anticonvulsant that blocks voltage-dependent sodium channels and enhances the activity of GABA at the GABA_A receptor.","indications":["Seizure prevention in patients with epilepsy","Migraine prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQaHRUMHlDaFFEanVRR3I1cFRuRFZYR3B3RW1Qdkt2cnpMTEJqQ1NnVUlDQmpQd0JsTTk3cmFmcVY2OEJSX2pXcmZUV2taODdsZGJKc2ZmMnhIYy1LekROaGpGWG5yaGpzbzNhRWx1ZTdYVllYZUpRalhZc2llSDNMbndzZm5FUlZiaDhYS2NaU05JWkFCVmE4TVhUbWw0YkdFMkxRNkxIdWg1UXYyNXVFT2s4UjFLM0ZXRFNVc0xwRUJ3X2Fzc0h2dVdYNHJ5UG55VlJRXy16Ym1UbmVkSnYzM0pGVEtxZWNIOUdwRjRRWFBsRTRN?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight - PR Newswire","headline":"Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in Myasthenia Gravis Market | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE9EbVJXdFZGVkxhUjhTdDlQLTVIbjFQTldqYTJPN2xZNWxCeVVMd2t6T0NXc1gtWm5ENUgzNHZrTldQMk1hN3J1QW5SQk0tN1hsejIxaXdPRHItNlFMcDZvckNPeWF2dkJHMUV0X0UxalAwNzl5LWhvZA?oc=5","date":"2025-02-02","type":"pipeline","source":"Time Magazine","summary":"Why Johnson & Johnson's CEO Welcomes Scrutiny - Time Magazine","headline":"Why Johnson & Johnson's CEO Welcomes Scrutiny","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPUDhVRHZmdTFDeXNmS2xSWjZpQW5pM2dfdUs2WTdjYlJQVFNyUnAwNXlpRGpuaENDTnFoS3ZocFN3UzNBZ0JEWTVxSWRnUGJtYUhHenpuS3RNcF9jaWp0UHh0YnUyOWZ1THhxOTlFR0hWdjQ4ZmhUaXVyZ0FfcmVUTkFHbnVKMF9iRlNEOFJ1d2lWbmZNN2c?oc=5","date":"2024-07-17","type":"deal","source":"Yahoo Finance","summary":"ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ - Yahoo Finance","headline":"ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQbDE4STVEdmJmc0tYSko4UzVjN3pJVnFDMGVKUGZfYzVPTVVvU2t0MDNxOUJmYmhsVXFMOHp4UGRKU0dGeHhMTFVmQm94M19MR3hHc2JZSktMMzVRQml1ZDRmQzQxU1dHUGxWTko4QnpjeWZYSHdpeC02SGExWkQ1ZjBMME84VEtwYjRCTVhObF9aN2JSeFFRZFNLVUlLQTQybVhEUGppNDdpcGhtNlBXaw?oc=5","date":"2024-02-25","type":"pipeline","source":"Fierce Biotech","summary":"UPDATE: J&J to shut down massive Bay Area R&D facility less than 18 months after opening it - Fierce Biotech","headline":"UPDATE: J&J to shut down massive Bay Area R&D facility less than 18 months after opening it","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOOTcxRUt6T19GbHNEVXE4c0NkRFhaZHZWNFRKbXFNZUxPWlNZT1NKbHNLdnBHYmplLXkxcTItSTBXWEFfWTdZQkxmQXdESnJGSm93RHVyQXg2Sko1aHJuWWpseEhhU2dNNktrVExSWVJUN2FMMEJlMXVuaUlTWkl6WlBfc0h6WUVZOFlMNWsxdTNfc1lUYl9kSkY2OURtMnpj?oc=5","date":"2023-09-15","type":"trial","source":"BioPharma Dive","summary":"J&J to phase out Janssen name in corporate rebrand - BioPharma Dive","headline":"J&J to phase out Janssen name in corporate rebrand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5uTHhxZm9lVFBidkZkTjZqdDdnYVZMaGpoOHFneEpLS3pBbW9heWtIRmNOTTREWlUwU3NoYms0ZUxLcjVlSFJscUtPR0RKNEVVdjN0Q3dwbW5ROXZRV1RWV2luTzd0VVQxby1aYmY5WUFBZlhZYVBtVy15cXB4Zw?oc=5","date":"2023-09-14","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Johnson & Johnson's rebrand: Focusing on pharma innovation - drugdiscoverytrends.com","headline":"Johnson & Johnson's rebrand: Focusing on pharma innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQXlRdnRqSVp2d1BHd0V2TkRBV2FlUTR6MVFPNUcwWmxoc0JBVUwySlZwSkEya01oaS1UZWVXQVBJblBfQnFWbjRpRnd3VjcySUI3bjZFdTl3WXFQRUNPYVBOUG9MYzJtS2EweXhWcXR3Ym9UWGxFVDNuXzR4blYtS2hON2dKdURGbXF2T2R1Q2Jwd0NrSFBGdWdTRnlSSWFhMk93MnlzaHVmanFReFJWbWgwNlhnY0JIdjYtd1B2dXZ0bVVnSGktb3pNS0owTnNwWm5kXw?oc=5","date":"2023-02-13","type":"pipeline","source":"Reuters","summary":"Johnson & Johnson names ex-Sanofi executive as pharma, R&D vice president - Reuters","headline":"Johnson & Johnson names ex-Sanofi executive as pharma, R&D vice president","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxOS0l2aEx2aHhueWFkQjlhRmJYQW1QY01TcW9uZEhmbUN0emIzeXNqTG4tZi1FQkREUHVoMlZxclJvbGExWC1SQ3FqSWRfWjBnanNwcXhHS19HM3A2QXp5eWpLZlJ3ekZ3aHdUeG5DTlUxT09YNWZ3dWZhYjJKdTJWQ3dsRVRCUlI4Nnh3QzNQR3RZVlZVZmhQcmlmeGI1dXd3VzNvMWRhVHM2aklua01BLWZrY0FTOUlCd0VMaTFYdUZIMEZnT2NaN3c2b1pKRFkyNmpoZ2JjbVZTOEVUeFBOR2JTU2FEZ20tZjVReG41a3JpLXoyYUcyRlBrX3lMV0RPcVJXQ21ibENsWFlZbzFhbXRfX2RIRmJpWTZocUNHejMyaVFVd0FUazZ5aGpGVWN6dFotWi1BM0hYVWVaVFFsTHdndHA4TVlFWXZyRkZtZlFLbG1aMmxQYnNKeEhwZVpNMXRR?oc=5","date":"2022-04-25","type":"pipeline","source":"PR Newswire","summary":"Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR) - PR ","headline":"Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxONzMxRmd1YVJIempZQ2tvZTBUbHZjNjAtdmU4QzcycThtcHNLQU54Z180d3lWMmNER2xzLWhKV2RxajgwWWJpd1AwUVhoRVZyZVg2aDFkcWJDay1TcW4weXRIRTdrMi1KcExGUnVXWTdFQl9KazVoZ3lCNlpfTGhFZHZEbHhlcTlkVHkxaFBzbmpkeTNaQkE?oc=5","date":"2021-07-09","type":"deal","source":"drugdiscoverytrends.com","summary":"Johnson & Johnson launches research partnerships network - drugdiscoverytrends.com","headline":"Johnson & Johnson launches research partnerships network","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOVHgwWWdtVUVnckFKWFk0ckUyZnRKNzRHd2VwT2ZEa04yWXJKYlZVVkpOdmhub0ticDRsZDFnQzRxVzFoZXR1RmRyTG85ekZqMjluOUpyUkE3c3c0eWhFV1pvNjZscnBFdGFLRURjcFVHUWo0SjVtZWpEd0hjdHg2blRrOXpzcEM4?oc=5","date":"2018-06-06","type":"pipeline","source":"Boston University","summary":"BU and Johnson & Johnson Innovation Team Up to Fight Lung Cancer - Boston University","headline":"BU and Johnson & Johnson Innovation Team Up to Fight Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE5JaVFjN0hDRUtjZ1pZZk1JVmNSN29yQURwRVR6Z2lRV3RicjlabGt4ZXhFemlqYi1xWFJoRE5HbFlmczVTb094QTUyZFQwV2lsVF9Td3E1STFKSEU?oc=5","date":"2017-03-23","type":"pipeline","source":"UC San Diego Today","summary":"A Dose of Research - UC San Diego Today","headline":"A Dose of Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPQWRfNHkzX09kY1pHUlMxdG5HbWUzMVhrTXByNF9LZFdDMDhIMEx5cGxVclRQVE9QSkdwM3FFY2V1dXdHTUc5Q0VQZUZSVmRfN3BqVVJMTUZ1SWJYOThudVpRcTByYW1lX3ZxdEU2cjgyenpzYlV6QUpmeXM4dGI1NlR1WVQzZGVRWGpXOF9FUXFxcW9CSklZM1BlVmVIeUNY?oc=5","date":"2013-04-08","type":"pipeline","source":"MIT Sloan Management Review","summary":"How Pharmaceuticals Can Avoid the Side Effects of Social Media - MIT Sloan Management Review","headline":"How Pharmaceuticals Can Avoid the Side Effects of Social Media","sentiment":"neutral"}],"patents":[],"drugCount":42,"phaseCounts":{"phase_3":24,"marketed":11,"phase_1":3,"phase_2":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}